What is Foundation Medicine worth?
What is Foundation Medicine worth?
The transaction is valued at $2.4 billion, and the total company is valued at $5.3 billion on a fully diluted basis. The merger agreement was approved unanimously by Roche’s board, a special committee of independent directors of Foundation Medicine, and Foundation’s full board with Roche members abstaining.
Does Roche own Foundation Medicine?
Roche to acquire a majority interest in Foundation Medicine of up to 56.3% on a fully diluted basis through a tender and acquisition of newly issued shares. Roche will tender for approximately 15.6 million Foundation Medicine shares at USD 50 per share with an aggregate tender value of approximately USD 780 million .
Who are the founders of Foundation Medicine?
Our founders, Eric Lander, Todd Golub, Matthew Meyerson and Levi Garraway, were key leaders in these efforts, and it was not long before they realized how important and transformative these research findings would be in the routine care of patients.
Who is the CEO of Foundation Medicine?
Cindy Perettie (Feb 4, 2019–)
Foundation Medicine/CEO
Brian Alexander, M.D., M.P.H., succeeds Cindy Perettie as chief executive officer of Foundation Medicine, Inc., a member of the CEO Roundtable on Cancer and a Gold Standard accredited employer. Previously Dr. Alexander was Foundation Medicine’s chief medical officer since 2019.
Is Foundation Medicine a non profit?
The collaboration brings together the EORTC, an independent, non-profit clinical research organization in cancer, and Foundation Medicine , a leader in molecular information that offers a suite of CGP assays that identifies the molecular alterations in an individual’s cancer to inform precision medicine treatment …
Is Foundation Medicine a laboratory?
Comprehensive results across all 324 genes, including bTMB, MSI-H status, and tumor fraction are reported as a laboratory professional service which is not reviewed or approved by the FDA.
Is Foundation Medicine a public company?
CAMBRIDGE, Mass. –(BUSINESS WIRE)– Foundation Medicine, Inc. today announced the pricing of its initial public offering of 5,888,888 shares of common stock at a price of $18.00 per share, before underwriting discounts.
When was Foundation Medicine acquired?
In 2016, using FoundationCore data, Foundation Medicine released anonymized records detailing genomic data on cancers from 18,000 adult patients to the National Cancer Institute’s (NCI) Genomic Data Commons (GDC) portal. In June, 2018, Roche announced it would acquire Foundation Medicine.
Is Foundation Medicine a private company?
Foundation Medicine is a Massachusetts-based biotechnology company that provides genomic profiling assays and clinical trail matching solutions for oncology research centers. Status: PrivateSubsidiary of F. Hoffmann-La Roche Ltd.
What is the stock symbol for Foundation Medicine?
Foundation Medicine trades on the NASDAQ under the ticker symbol “FMI.”
How much does Foundation one cost?
The list price of FoundationOne® and FoundationACT® are $5,800, and the list price of FoundationOne Heme is $7,200. These are the amounts that are billed to your insurance. If you are uninsured, or if you have insurance and cannot afford the applicable out-of-pocket cost, you have options.
Is Grail a public company?
Currently, Grail isn’t publicly traded on its own, although it did file for an IPO in September of 2020. The company’s primary product, which has been in development for several years, is Galleri, which is a detection test to help diagnose cancer in much earlier stages than is currently possible.
https://www.youtube.com/user/FoundationMedicine
